RA0434

antibody from Oursmab
Targeting: ITGB2 CD18, LFA-1, MAC-1, MFI7
Provider product page for RA0434
Western blot
ELISA
Immunocytochemistry
Flow cytometry
Functional assay

Antibody data

Product number
RA0434 - Provider product page
Provider
Oursmab
Product name
Erlizumab (Biosimilar Reference Antibody) (ITGB2)
Antibody type
Monoclonal
Description
Erlizumab (development code rhuMAb-CD18) was an investigational, humanized monoclonal IgG1 antibody developed for the treatment of acute conditions involving inflammatory tissue damage, such as stroke and myocardial infarction (heart attack). It functioned as a leukocyte adhesion inhibitor. Its proposed mechanism of action was to bind to the CD18 subunit of leukocyte integrins on the surface of neutrophils and other white blood cells. This binding aimed to block the critical interaction between these integrins (like LFA-1 and Mac-1) and adhesion molecules (ICAM-1) on activated vascular endothelial cells. By inhibiting leukocyte adhesion and subsequent transmigration into ischemic or inflamed tissues, erlizumab was designed to reduce the secondary inflammatory damage that exacerbates primary injury in stroke and heart attack.
Reactivity
Human
Isotype
IgG
Vial size
100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg
Concentration
Bottled at the concentration indicated on the vial.
Storage
Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.
ITGB2 protein structure - RA0434 shown in red.